We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Opinions expressed are those of the authors and not of Oxford University. Readers' comments will be moderated - see our guidelines for further information.
A major new study has shown that the risk of hospital admissions for young babies with serious respiratory infections reduced by more than 80% in Scotland following a new maternal vaccination programme against respiratory syncytial virus (RSV).
A Boots pharmacy in Durham is recruiting patients to the DURATION trial, testing whether community pharmacies can support clinical research following the NHS Pharmacy First rollout. The pilot could reshape how primary care trials adapt to changing patient pathways.
A Department Clinical Trials Unit coordinated trial has found most penicillin 'allergies' are not real. Safely removing these incorrect labels can lead to better patient treatment and is a vital step in tackling the global threat of antimicrobial resistance.
An international team, led the Nuffield Department of Primary Care Health Sciences, is calling for a fundamental shift in how we conduct health research to better serve our real-world health and care needs.
New UK-wide Centre for Applied Respiratory Research, Innovation and Impact (CARRii) launches at Oxford, aiming to reduce hospital admissions and health inequalities in respiratory care through innovative research and technology.
Can the long-term consequences of COVID 19 be reduced through the use of novel antiviral medicines? New research from the PANORAMIC trial, run in NDPCHS Clinical Trial Unit and funded and delivered by the NIHR, has found that treating vaccinated, higher-risk adults with COVID-19 with the antiviral drug molnupiravir offers only modest benefits when it comes to reducing long term effects of the acute illness.